Compare Adaptive Biotechnologies Corp (ADPT) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nebius Group NV — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Nebius Group NV trades at $205.87 (market cap $49.56B). The key difference: Nebius Group NV is far larger — about 14.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ADPT | NBIS | |
|---|---|---|
Market Cap | $3.33B | $49.56B |
Sector | Health | Technology |
52-Week High | $22.37 | $286.69 |
52-Week Low | $10.24 | $44.30 |
Enterprise Value | $3.19B | $49.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NBIS trades at $213.02, down 1.21% with bearish technical signals despite strong analyst support. The stock shows premium valuations (P/E 82.25, P/S 64.41) but impressive profitability (93.09% net margin) and robust revenue growth projections from $530M to $878M. Recent volatility stems from Meta's potential cloud competition, though news highlights Nebius's AI infrastructure strength and institutional buying interest.
Outlook remains positive with 87.5% analyst buy ratings and $233.13 consensus target, but high valuation and competitive risks from tech giants temper near-term upside. Cash flow trends show aggressive expansion funding, while earnings beats/misses reflect execution volatility in a high-growth sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
